GBA1 and Parkinson disease: This finding has led to the suggestion that the GBA1 mutations act through a dominant toxic gain-of-function mechanism to cause PD and DLB, perhaps by seeding α-synuclein aggregates via a prion-like mechanism [37–39, 44].